Skip to Content

Solifenacin Pregnancy and Breastfeeding Warnings

Solifenacin is also known as: VESIcare

Solifenacin Pregnancy Warnings

Animal studies have failed to reveal evidence of embryotoxicity or teratogenicity when exposed to 1.2 times the maximum recommended human dose (30 mg/kg/day). Reduced fetal body weight has been observed in mice when exposed to 3.6 times the maximum recommended human dose (100 mg/kg). An increase incidence in cleft palate has been reported in mice exposed to 7.9 the maximum recommended human dose (250 mg/kg).

Solifenacin has been assigned to pregnancy category C by the FDA. There are no controlled data in human pregnancy. Solifenacin is only recommended for use during pregnancy when benefit outweighs risks.

See references

Solifenacin Breastfeeding Warnings

There are no data on the excretion of solifenacin into human milk. Solifenacin is excreted into the milk of mice. The manufacturer recommends that solifenacin not be used during nursing. A decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. VESIcare (solifenacin)." GlaxoSmithKline, Research Triangle Park, NC.

References for breastfeeding information

  1. "Product Information. VESIcare (solifenacin)." GlaxoSmithKline, Research Triangle Park, NC.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.